A Open-label, Double arms, pilot Phase II study in single centre to Evaluate the Efficacy of early conversion to Osimertinib Versus continue to First-generation EGFR-TKIs in patients with acquired T790M mutation positive in EGFR-mutant NSCLC patients after Treating with First-generation EGFR-TKIs
Latest Information Update: 12 Jun 2018
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Jun 2018 New trial record